leadf
logo-loader
viewCardiol Therapeutics

Cardiol Therapeutics receives FDA approval for Phase 2/3 COVID-19 trial with CardiolRX

Cardiol Therapeutics Inc. (TSE: CRDL-OTCQX: CRTPF) President and CEO David Elsley joined Steve Darling from Proactive with news the company has been given the go-ahead for an investigational new drug application to commence a Phase II/III, double-blind, a placebo-controlled clinical trial investigating the efficacy and safety of CardiolRx.

Elsley talks about how and where this study is going to be conducted and he also talked about timing for CardiolRX and how this now speeds up the development.

Quick facts: Cardiol Therapeutics

Price: 2.7 CAD

TSX:CRDL
Market: TSX
Market Cap: $88.59 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cardiol Therapeutics named herein, including the promotion by the Company of Cardiol Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Cardiol Therapeutic’s Cortalex THC free CBD product now available at...

Cardiol Therapeutics (TSX: CRDL- OTCQX: CRTPF) President and CEO David Elsley joined Steve Darling from Proactive with news the company now has a product on the Medical Cannabis By Shoppers Platform. Elsley telling Proactive, Cortalex a THC-free* extra-strength oral CBD formulation, is now...

on 10/22/2020

2 min read